ACADIA Pharmaceuticals Inc (ACAD)

38.88
NASDAQ : Health Care
Prev Close 39.56
Day Low/High 38.16 / 39.43
52 Wk Low/High 17.02 / 42.49
Avg Volume 2.45M
Exchange NASDAQ
Shares Outstanding 121.11M
Market Cap 4.79B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

In addition to Sage Therapeutics, also moving biotech Friday: Novavax, Cytokinetics and Acadia Pharmaceuticals.

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Welcome to the Small-Cap Biotech Mailbag!

Welcome to the Small-Cap Biotech Mailbag!

We answer recent reader questions about three of the biotech stocks we regularly cover.

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

The company's shares jumped 5% midday Friday on rumors that Astrazeneca could buy Acadia.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

Allergan, Apple, Facebook: Doug Kass' Views

Allergan, Apple, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.

Allergan, Citigroup, Apple: Doug Kass' Views

Allergan, Citigroup, Apple: Doug Kass' Views

Doug Kass shares his thoughts on how he had one of his best days in recent memory, and warns you not to look in the rear view mirror.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

3 Biotechs Screaming 'Takeover Target'

3 Biotechs Screaming 'Takeover Target'

M&A activity should perk up substantially in the small and mid-cap space this year.

Hey, What About the Transports?

They were red today and no one seems to care.

ACADIA Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference On January 10, 2017

ACADIA Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference On January 10, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Starbucks, Allergan, Amazon: Doug Kass' Views

Starbucks, Allergan, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'

Acadia Pharmaceuticals Soars After Positive Alzheimer's Disease Study

Acadia Pharmaceuticals Soars After Positive Alzheimer's Disease Study

Shares of Acadia jumped Tuesday after the bio-pharmaceutical company reported positive results for a drug used for Alzehimer's patients.

Acadia Pharma Takes Low Road to Justify Drug Push Into Alzheimer's Psychosis

Acadia Pharma Takes Low Road to Justify Drug Push Into Alzheimer's Psychosis

Acadia Pharmaceuticals uses scant, mediocre clinical data to justify moving Nuplazid into a late-stage clinical trial of Alzheimer's disease psychosis.

ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study Of Pimavanserin For Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study Of Pimavanserin For Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced positive top-line results from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis (AD Psychosis).

Allergan, Apple, Oakland Capital: Doug Kass' Views

Allergan, Apple, Oakland Capital: Doug Kass' Views

Doug Kass shares his thoughts on China and life insurers.

This Rally May Not Be Done, but It's Close

Friday’s action was enough for me to believe we’re near a real pullback.

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder

ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of CLARITY,...

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

Apple Continues to Underperform; the Market Is Resistant: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how Apple is still a short for him and that the market is still resistant.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

4 Promising Small Biotechs to Watch in 2017

4 Promising Small Biotechs to Watch in 2017

Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.